Faculty of Medicine, Department of Pediatric Hematology, Yüzüncü Yıl University, 65200 Van, Turkey.
Target Oncol. 2010 Dec;5(4):291-4. doi: 10.1007/s11523-010-0161-6. Epub 2010 Sep 22.
Monoclonal antibodies have provided new promise for patients with B-cell malignancies. Rituximab is a monoclonal antibody against B-lymphocytes that express CD20; it is used for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Very few data are available regarding the treatment of children with non-Hodgkin lymphoma with rituximab. In this article, we reported three children with primary refractory/relapsed B-cell-non-Hodgkin lymphoma, who were successfully treated with a combination of intensive chemotherapy protocol plus rituximab. In all three of our cases, the patients are still in complete remission. Our aim is to emphasize the importance of use of rituximab in the treatment of childhood B-cell non-Hodgkin lymphoma.
单克隆抗体为 B 细胞恶性肿瘤患者带来了新的希望。利妥昔单抗是一种针对表达 CD20 的 B 淋巴细胞的单克隆抗体，用于治疗复发性或难治性 B 细胞非霍奇金淋巴瘤患者。关于利妥昔单抗治疗儿童非霍奇金淋巴瘤的数据非常有限。在本文中，我们报告了三例原发性难治/复发 B 细胞非霍奇金淋巴瘤患儿，他们成功地接受了强化化疗方案加利妥昔单抗的联合治疗。在我们所有的三个病例中，患者均处于完全缓解状态。我们的目的是强调利妥昔单抗在儿童 B 细胞非霍奇金淋巴瘤治疗中的重要性。
